Abel, Mary Kathryn
Melisko, Michelle E.
Rugo, Hope S.
Chien, A. Jo
Diaz, Italia
Levine, Julia K.
Griffin, Ann http://orcid.org/0000-0003-0837-6515
McGuire, Joseph
Esserman, Laura J. http://orcid.org/0000-0001-9202-4568
Borno, Hala T.
Mukhtar, Rita A. http://orcid.org/0000-0001-8079-7846
Article History
Received: 16 March 2021
Accepted: 8 October 2021
First Online: 25 October 2021
Competing interests
: Dr. Melisko receives research funding from Astra Zeneca, Novartis, KCRN Research, and Puma and consulting fees from Biotheranostics. Dr. Rugo receives research support for clinical trials through the University of California from Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi, Seattle Genetics, Eisai, Macrogenics, Sermonix, Immunomedics, and AstraZeneca. She has also received travel support from Daiichi, Mylan, Pfizer, Merck, AstraZeneca, Novartis, and Macrogenics and honoraria from Puma, Mylan, and Samsung. Dr. Chien receives research funding from Merck, Puma, Amgen, and Seattle Genetics. Dr. Esserman is an unpaid member of the board of directors of Quantum Leap Healthcare Collaborative and receives research funding from QLHC for the I-SPY TRIAL. She is a member of the Blue Cross/Blue Shield Medical Advisory Panel and receives honoraria and travel funding. She has a grant from Merck for an Investigator-initiated trial of DCIS. The remaining authors declare no competing interests.